Results 181 to 190 of about 22,968 (195)

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Lancet Oncology, The, 2015
Richard Finn, Katalin Boer, Johannes Ettl   +2 more
exaly  

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Annals of Oncology, 2021
exaly  

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Lancet Oncology, The, 2016
Massimo Cristofanilli, Igor N Bondarenko, Seock-Ah Im   +2 more
exaly  

p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition

Science, 2019
Keelan Z Guiley, Jack W Stevenson, Kevin Lou   +2 more
exaly  

Palbociclib

Reactions Weekly, 2015
openaire   +1 more source

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

Cancer Discovery, 2018
Ben O'Leary, Yuan Liu, Fabrice Andre
exaly  

Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells

Cancer Letters, 2018
Jin Won Kim, Kyung-hun Lee, Tae-Yong Kim
exaly  

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

Annals of Oncology, 2018
Luca Malorni, Fabio Puglisi, Giuseppe Curigliano   +2 more
exaly  

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial

Lancet Oncology, The, 2019
Kevin Palka, Juneko E Grilley-Olson, Ronald J Maggiore   +2 more
exaly  

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma

Gut, 2017
Julien Bollard, Marina Ruiz de Galarreta, Daniela Sia   +2 more
exaly